Loading patent…
AssigneeAcerta Pharma B.V.
InventorsAhmed Hamdy, Wayne Rothbaum, Raquel Izumi, Brian Lannutti, Todd Covey, Roger Ulrich, Dave Johnson, Tjeerd Barf, Allard Kaptein
Estimating the term…
In some embodiments, the invention includes a therapeutic combination of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the γ- and δ-isoforms and selective for both γ- and δ-isoforms, and a Bruton's tyrosine kinase (BTK) inhibitor. In some embodiments, the invention includes therapeutic methods of using a BTK inhibitor and a PI3K-δ inhibitor to treat solid tumor cancers by modulation of the tumor microenvironment, including macrophages, monocytes, mast cells, helper T cells, cytotoxic T cells, regulatory T cells, natural killer cells, myeloid-derived suppressor cells, regulatory B cells, neutrophils, dendritic cells, and fibroblasts.
A method of treating a hyperproliferative disorder in a subject, comprising co-administering to a subject in need thereof a therapeutically effective amount of a phosphoinositide 3-kinase (PI3K) inhibitor in combination with a Bruton's tyrosine kinase (BTK) inhibitor, wherein the PI3K inhibitor is:
Dependencies are inferred from the claim text.